Sunshield Chemicals Limited has taken a significant step towards its planned rights issue, as announced in a recent corporate filing. The company's Rights Issue Committee convened on August 6, 2025, to approve the Draft Letter of Offer, marking a crucial milestone in the capital raising process.

Key Developments

• The Rights Issue Committee of Sunshield Chemicals' Board of Directors met on August 6, 2025.
• The committee approved the Draft Letter of Offer for the company's upcoming rights issue.
• The draft will be submitted to BSE Limited for in-principle approval.

Regulatory Compliance

Sunshield Chemicals Limited has promptly informed the stock exchange about this development, adhering to the compliance requirements set forth by the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015.

Company Details

What's Next

Investors and market participants will be watching for further developments in Sunshield Chemicals' rights issue process. The next crucial step will be obtaining in-principle approval from BSE Limited, which will pave the way for the company to proceed with its capital raising plans.

It's important to note that while the Draft Letter of Offer has been approved, the specifics of the rights issue, such as the issue size, pricing, and ratio, have not been disclosed in the current announcement. Shareholders and potential investors are advised to await further communications from the company for more details on the rights issue.

As this process unfolds, it could potentially impact the company's capital structure and provide existing shareholders with an opportunity to increase their stake in Sunshield Chemicals Limited.

Sunshield Chemicals Limited has announced significant corporate decisions following its Board of Directors meeting held on July 31, 2025. The company has approved a fresh rights issue and restructured its key board committees, signaling important changes in its financial and governance strategies.

Rights Issue Approval

The Board of Directors has given the green light to a rights issue aimed at raising up to Rs. 150.00 crores through the issuance of equity shares. This decision comes after withdrawing a previous draft letter of offer dated September 30, 2024, and superseding a rights issue approval granted on August 9, 2024. The fresh rights issue will be offered to eligible shareholders, with the specifics to be determined by a newly authorized Rights Issue Committee.

Key points of the rights issue include:

• Maximum fund-raising target: Rs. 150.00 crores
• Offered to: Eligible equity shareholders as of a to-be-determined Record Date
• Compliance: In accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018

The Rights Issue Committee has been empowered to decide on crucial aspects such as:

• Issue price
• Entitlement ratio
• Record date
• Timing of the issue
• Appointment of intermediaries
• Other terms and conditions

Board Committee Restructuring

Effective October 21, 2025, Sunshield Chemicals will implement a reconstitution of three key committees:

1. Audit Committee
2. Nomination and Remuneration Committee
3. Stakeholders Relationship Committee

The restructured committees will be composed as follows:

Notably, Mr. Jeet Malhotra, the Managing Director & CEO, will be a permanent invitee to the Audit Committee meetings.

Financial Results and Trading Window

The Board has also approved the unaudited financial results for the quarter ended June 30, 2025. The company's auditors have issued an unmodified report on these results. Following this announcement, the trading window for dealing in the company's securities will reopen 48 hours after the declaration of the financial results.

These strategic decisions reflect Sunshield Chemicals' efforts to strengthen its financial position and enhance its corporate governance structure. Investors and market watchers will be keenly observing how these changes impact the company's future performance and market standing.